MCAS: Mast Cell Activation Syndrome

Stabilizing mast cells helps. But mast cells don't activate themselves. The patient who reacts to everything is reacting to something — and identifying what's activating the system is what makes treatment work.

What patients tell us

“I react to everything — foods I used to tolerate, smells, weather changes, stress, exercise. The list keeps growing. Antihistamines help a little but not enough. I've been told my allergy tests are normal so there's nothing to investigate. Something is clearly wrong, and no one's identifying what.”

What MCAS is

Mast cell activation syndrome is a clinical condition in which mast cells — immune cells distributed throughout the body — release histamine and a wide array of other inflammatory mediators inappropriately or excessively. The release happens in response to triggers that wouldn't normally provoke this kind of immune response, in response to multiple triggers simultaneously, or in sustained patterns rather than the acute response-and-resolution cycle of normal mast cell function.

The clinical picture is multi-system because mast cells are present in nearly every tissue. The mediators they release affect blood vessels, the respiratory tract, the skin, the gastrointestinal tract, the nervous system, and broader immune function. Patients commonly experience symptoms across most or all of these systems, often with variability that reflects the episodic nature of mediator release.

How MCAS is recognized

The diagnostic criteria for MCAS require three components: a clinical pattern consistent with mast cell mediator release affecting multiple organ systems; evidence of mediator elevation when symptomatic; and clinical response to mast cell-directed treatment. The episodic nature of mediator release means a patient with clear clinical MCAS may have normal baseline mediator levels — testing during symptom flares is what produces yield. Standard IgE-mediated allergy testing identifies classic allergy, not MCAS, which is why patients are so often told their reactions 'aren't really allergic' — technically accurate, clinically unhelpful.

What activates mast cells in MCAS

Mast cells are activated by an extensive list of triggers, many of which overlap directly with the driver domains in the 5M Model. Mycotoxin exposure — particularly chronic exposure from water-damaged buildings — is one of the most consistent triggers. Chronic infections sustain mast cell activation through ongoing immune signaling. Heavy metal accumulation can contribute to immune dysregulation patterns that include mast cell involvement. Hormonal factors influence mast cell function — estrogen in particular is mast cell-activating. Dysbiotic gut bacteria, food sensitivities, environmental chemicals, physical triggers, and psychological stress all add to the trigger burden.

How iHeal evaluates and treats MCAS

The evaluation combines clinical pattern recognition, mediator testing where it's likely to be useful, and identification of the contributors driving mast cell activation. Treatment combines mast cell stabilization — H1 and H2 antihistamines, mast cell stabilizers, leukotriene modifiers, and in some cases low-dose naltrexone — with driver reduction. Driver reduction is what allows the treatment to ultimately work rather than just suppress symptoms. Over time, with both stabilization and driver reduction, patients' reactivity thresholds tend to rise.

Dr. Matthew Everett, MD

Pro Tip · From Dr. Everett

Matthew Everett, MDEnvironmental Medicine · IFMCP

The evaluation combines clinical pattern recognition, mediator testing where it's likely to be useful, and identification of the contributors driving mast cell activation. Treatment combines mast cell stabilization — H1 and H2 antihistamines, mast cell stabilizers, leukotriene modifiers, and in some cases low-dose naltrexone — with driver reduction. Driver reduction is what allows the treatment to ultimately work rather than just suppress symptoms. Over time, with both stabilization and driver reduction, patients' reactivity thresholds tend to rise.

Sources & Further Reading

  • AAAAI: Mast Cell Activation Syndrome aaaai.org/conditions-treatments/related-conditions/mcas
  • The Mast Cell Disease Society tmsforacure.org
  • Peer-Reviewed: Afrin et al. on MCAS diagnostic criteria — Published in American Journal of Medicine and other peer-reviewed journals; PubMed-indexed
  • Peer-Reviewed: Theoharides et al. on mast cell activation — Published in peer-reviewed immunology journals; PubMed-indexed

Concerned this applies to you?

A consultation is where we figure out whether mcas is actually contributing to your symptoms — and what to do about it.

On This Page

MCAS: Mast Cell Activation Syndrome

Stabilizing mast cells helps. But mast cells don't activate themselves. The patient who reacts to everything is reacting to something — and identifying what's activating the system is what makes treatment work.

What patients tell us

“I react to everything — foods I used to tolerate, smells, weather changes, stress, exercise. The list keeps growing. Antihistamines help a little but not enough. I've been told my allergy tests are normal so there's nothing to investigate. Something is clearly wrong, and no one's identifying what.”

What MCAS is

Mast cell activation syndrome is a clinical condition in which mast cells — immune cells distributed throughout the body — release histamine and a wide array of other inflammatory mediators inappropriately or excessively. The release happens in response to triggers that wouldn't normally provoke this kind of immune response, in response to multiple triggers simultaneously, or in sustained patterns rather than the acute response-and-resolution cycle of normal mast cell function.

The clinical picture is multi-system because mast cells are present in nearly every tissue. The mediators they release affect blood vessels, the respiratory tract, the skin, the gastrointestinal tract, the nervous system, and broader immune function. Patients commonly experience symptoms across most or all of these systems, often with variability that reflects the episodic nature of mediator release.

How MCAS is recognized

The diagnostic criteria for MCAS require three components: a clinical pattern consistent with mast cell mediator release affecting multiple organ systems; evidence of mediator elevation when symptomatic; and clinical response to mast cell-directed treatment. The episodic nature of mediator release means a patient with clear clinical MCAS may have normal baseline mediator levels — testing during symptom flares is what produces yield. Standard IgE-mediated allergy testing identifies classic allergy, not MCAS, which is why patients are so often told their reactions 'aren't really allergic' — technically accurate, clinically unhelpful.

What activates mast cells in MCAS

Mast cells are activated by an extensive list of triggers, many of which overlap directly with the driver domains in the 5M Model. Mycotoxin exposure — particularly chronic exposure from water-damaged buildings — is one of the most consistent triggers. Chronic infections sustain mast cell activation through ongoing immune signaling. Heavy metal accumulation can contribute to immune dysregulation patterns that include mast cell involvement. Hormonal factors influence mast cell function — estrogen in particular is mast cell-activating. Dysbiotic gut bacteria, food sensitivities, environmental chemicals, physical triggers, and psychological stress all add to the trigger burden.

How iHeal evaluates and treats MCAS

The evaluation combines clinical pattern recognition, mediator testing where it's likely to be useful, and identification of the contributors driving mast cell activation. Treatment combines mast cell stabilization — H1 and H2 antihistamines, mast cell stabilizers, leukotriene modifiers, and in some cases low-dose naltrexone — with driver reduction. Driver reduction is what allows the treatment to ultimately work rather than just suppress symptoms. Over time, with both stabilization and driver reduction, patients' reactivity thresholds tend to rise.

Dr. Matthew Everett, MD

Pro Tip · From Dr. Everett

Matthew Everett, MDEnvironmental Medicine · IFMCP

The evaluation combines clinical pattern recognition, mediator testing where it's likely to be useful, and identification of the contributors driving mast cell activation. Treatment combines mast cell stabilization — H1 and H2 antihistamines, mast cell stabilizers, leukotriene modifiers, and in some cases low-dose naltrexone — with driver reduction. Driver reduction is what allows the treatment to ultimately work rather than just suppress symptoms. Over time, with both stabilization and driver reduction, patients' reactivity thresholds tend to rise.

Sources & Further Reading

  • AAAAI: Mast Cell Activation Syndrome aaaai.org/conditions-treatments/related-conditions/mcas
  • The Mast Cell Disease Society tmsforacure.org
  • Peer-Reviewed: Afrin et al. on MCAS diagnostic criteria — Published in American Journal of Medicine and other peer-reviewed journals; PubMed-indexed
  • Peer-Reviewed: Theoharides et al. on mast cell activation — Published in peer-reviewed immunology journals; PubMed-indexed

Concerned this applies to you?

A consultation is where we figure out whether mcas is actually contributing to your symptoms — and what to do about it.

On This Page